GotoPER - Physicians' Education Resource

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

09/09/2022

Register Now

September 9, 2022, 7:00 AM - 8:00 AM CT

Overview

Optimal therapy of patients with non–small cell lung cancer (NSCLC) depends on complete molecular characterization of the tumor, as patients with oncogene-driven disease are often best treated with targeted therapy. For patients without an actionable oncogenic driver, PD-L1 testing is important to determine the best immunotherapy-based regimen. Assessment of these different markers involves a range of approaches to testing and interpretation of results.

This pathologist-led program will illustrate how molecular testing results translate into therapeutic decisions. Participants will be able to see how to address challenges in both testing and treatment settings through case-based discussions. Attendees will also have the opportunity to ask questions directly of the expert faculty.

Benefits of Attending

  • Learn about best multidisciplinary practices for molecular testing in NSCLC
  • Gain insight into the interpretation and application of testing results to therapy
  • Hear experts discuss how to address challenges in testing and treatment for patients with NSCLC

Target Audience

This educational program is directed toward the American Society for Clinical Pathology (ASCP) audience, primarily pathologists and other health care professionals involved in the diagnosis and treatment of cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify the role of multidisciplinary team members in addressing barriers to testing and the interpretation of molecular test results for patients with advanced NSCLC
  • Evaluate current and emerging molecular biomarkers that facilitate treatment personalization in patients with advanced NSCLC
  • Explain key efficacy and safety data, as well as treatment guidelines, concerning the integration of current targeted therapies and immunotherapy into clinical practice for advanced NSCLC management
  • Discuss emerging therapeutic targets and treatment strategies in the management of patients with advanced NSCLC

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Acknowledgment of Commercial Support

    This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Exact Sciences.

    See all upcoming events

    Related Content